Market News & Trends
Foamix Receives FDA Approval for Topical Treatment
Foamix Pharmaceuticals Ltd. recently announced the US FDA has approved its novel AMZEEQ (minocycline) topical foam, 4%. AMZEEQ, formerly known as FMX101, is indicated for…
Theralase Granted European Patent for Anti-Cancer Photo Dynamic Compounds
Theralase Technologies Inc. recently announced the company has been granted a European Patent for their anti-cancer PDCs, which will issue in due course. The patent,…
Genedata & Merck Co-Develop Digital Platform
Genedata recently announced the successful completion of a multi-year software development project in close collaboration with Merck, a leading science and technology company. Fulfilling Merck’s…
BD Launches Two-Step Disposable Autoinjector
BD (Becton, Dickinson and Company) recently announced the launch of the BD Intevia 1 mL two-step disposable autoinjector, a robust platform device combining autoinjector and…
CombiGene Signs Agreement With Cobra Biologics
CombiGene AB recently signed an agreement with the Anglo-Swedish Contract Development and Manufacturing Organisation (CDMO) Cobra Biologics (Cobra) for production of candidate drug CG01. The…
Adaptate Biotherapeutics Formed to Develop Antibody-Based Therapies That Modulate Gamma Delta T-Cells
GammaDelta Therapeutics, a company focussed on harnessing the unique properties of gamma delta T-cells to develop transformational immunotherapies, recently announced the formation of a spin-out…
Yourway Mitigates Uncertainty of Brexit for Clinical Trials In Europe
Yourway, the only truly integrated premium courier and clinical packager in the industry, announced its establishment of a new location within the European Union providing…
Novavax Initiates Pivotal Phase 3 Clinical Trial
Novavax, Inc. recently announced the initiation of a pivotal Phase 3 clinical trial for NanoFlu, its recombinant quadrivalent seasonal influenza vaccine candidate, in adults aged…
Orgenesis Announces Co-Development Agreement With Accellix
Orgenesis Inc recently announced it has entered into a co-development agreement with Accellix, Inc. The agreement will enable Orgenesis to integrate Accellix’s proprietary optic system, cartridges, reagents,…
An End to Alzheimer’s? New Drugs Fight Memory Loss
Researchers in Toronto have developed an experimental drug that appears to renew the underlying brain impairments causing memory loss, fuelling hopes that a treatment for…
EXCLUSIVE ONLINE CONTENT
Molex Expands European Manufacturing Footprint & Capabilities With State-of-the-Art Campus in Poland
Molex recently announced a major expansion of its global manufacturing footprint with the opening of a new campus in Katowice, Poland. The facility’s initial 23,000-square-meter manufacturing space will….
Kala Pharmaceuticals Completes Sale of EYSUVIS & INVELTYS to Alcon Inc
Kala Pharmaceuticals, Inc. recently announced it has completed the sale of its commercial portfolio and related intellectual property assets to Alcon Inc., a transaction that was….
Insightful Science Acquires Protein Metrics to Expand its R&D Solution to Include Proteomics
Insightful Science recently announced it has completed the transaction to acquire Protein Metrics, Inc. to expand the company’s R&D value chain to widen the biopharmaceutical protein analysis arena….
Acer Therapeutics & Relief Therapeutics Announce NDA Submission for ACER-001 for Treatment of Urea Cycle Disorders
Acer Therapeutics Inc. Relief Therapeutics recently announced the submission of a New Drug Application (NDA) to the US FDA for ACER-001 (sodium phenylbutyrate) for the treatment of Urea Cycle Disorders (UCDs)….